ArticleFrontiers in immunology2026
Prognostic value of lymphatic vessel density in the capsule of early-stage hepatocellular carcinoma: implications for postoperative recurrence risk.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Diagnostic accuracy of circulating long noncoding RNAs in hepatocellular carcinoma: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Comparison of proton vs. photon radiotherapy for liver cancer: a meta-analysis.BMC gastroenterology · 2026Pooled it
- Circular RNAs in hepatocellular carcinoma: a systematic qualitative review of regulatory mechanisms, therapeutic resistance, and clinical translation.BMC gastroenterology · 2026Pooled it
- Diagnostic performance of artificial intelligence models in hepatocellular carcinoma: a systematic review and diagnostic meta-analysis.BMC gastroenterology · 2026Pooled it
- Preoperative gamma-glutamyltransferase-to-lymphocyte ratio and prognosis after curative hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Moderate alcohol consumption and clinical outcomes in MASLD: a systematic review and meta-analysis of longitudinal cohorts.BMC gastroenterology · 2026Pooled it
- Is PD-1/PD-L1 inhibitor plus bevacizumab superior to sorafenib as first-line treatment for advanced hepatocellular carcinoma? A pooled analysis of four phase 3 RCTs.BMC gastroenterology · 2026Pooled it
- Advances in oncolytic viruses immunotherapy of hepatocellular carcinoma.Discover oncology · 2026Review
- Experimental models in immuno-oncology and their translational impact.Discover oncology · 2026Review
- POTEF upregulation drives hepatocellular carcinoma progression via oncogenic signaling and immune modulation.Scientific reports · 2026Article
- Sarcopenia modifies the survival benefit of triple therapy versus TACE alone in elderly patients with unresectable hepatocellular carcinoma: A multicenter retrospective cohort study.Scientific reports · 2026Article
- Multi-omics integration model of exosome metabolomics and PD-1/PD-L1 expression for early prediction of immunotherapy efficacy in advanced liver cancer.Scientific reports · 2026Article
- Predictors and outcomes of hepatic decompensation following transarterial locoregional therapy in hepatocellular carcinoma.Scientific reports · 2026Article
- A bibliometric analysis of research trends and hotspots on recurrence after thermal ablation for hepatocellular carcinoma 2005-2025.Discover oncology · 2026Article
- KIF23 in disease pathogenesis and its therapeutic and diagnostic potential.Discover oncology · 2026Review
- Temperature-sensitive liquid embolic agent loaded with Lobaplatin in the TACE procedure for rabbit VX2 liver tumor.Scientific reports · 2026Article
- Tumor capsule status modifies the survival impact of anatomical versus non-anatomical hepatectomy in early-stage hepatocellular carcinoma: a multicenter retrospective study.World journal of surgical oncology · 2026Article
- Atractylon inhibits hepatocellular carcinoma by inducing ferroptosis with increasing SLC39A14 expression.Scientific reports · 2026Article
- Serum creatinine to cystatin C ratio and risk of incident digestive diseases in middle-aged and older adults: a prospective national cohort study.Scientific reports · 2026Article
- Electronic nose versus gas chromatography - mass spectrometry for diagnostic discrimination of advanced hepatocellular carcinoma by volatolomic analysis.BMC gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Lymphatic vessels are present in the capsule of hepatocellular carcinoma (HCC) at an early stage, but their value in the prognosis remains unclear. The study aimed to evaluate the prognostic impact of lymphatic vessels in the tumor capsule on patients with HCC at Barcelona Clinic Liver Cancer (BCLC) stages 0-A. This is one of the first studies to investigate the tumor capsule specifically. Methods: This retrospective study included HCC patients at BCLC stages 0-A, who underwent radical liver resection between January 2017 and December 2020. Lymphatic vessel density (LVD) in the tumor capsule was determined by immunohistochemistry using anti-D2-40. Patients were stratified into the high and low LVD groups. Their overall survival (OS) and recurrence-free survival (RFS) were analyzed. The potential risk factors affecting survival and for predicting microvascular invasion (MVI) or satellite nodules were analyzed using Cox regression analysis and logistic regression analysis, respectively. Results: A total of 212 patients were included (180 male and 142 patients < 60 years old). The 1, 3, and 5-year OS were 76.5%, 52.9%, and 41.2% in the high LVD group, versus 94.4%, 76.4%, and 69.0% in the low LVD group ( Conclusions: High LVD in the tumor capsule was associated with worse OS, RFS, and intrahepatic spread (MVI and satellite nodules) in patients with HCC at BCLC stages 0-A after liver resection. Our findings suggest that assessing LVD in the tumor capsule could serve as a useful tool in predicting postoperative prognosis and guiding personalized treatment strategies for patients with early-stage HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.